Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?

Liropiprant a prostaglandin receptor antagonist was designed as a codrug to minimize these unpleasant side effects.[ 9 ] But, more recently “HPS2 THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events)” study done to assess the cardiovascular benefit of nicotinic acid/liropiprant combination in addition to statin +/- ezetimibe with a prestudy LDL cholesterol concentration of <130 mg/dL on over 40,000 patients across the globe showed highly significant four fold increased risk of myopathy in the study group compared to placebo and also double (0.9-0.4%) the incidence of diabetic complications (typically hyperglycemia)[ 10 ] needing early termination of the study raising serious concerns about the safety of this approach.

also in 132,142 other papers